Janssen-Cilag changes wholesaling arrangements in the UK
This article was originally published in Scrip
Janssen-Cilag(Johnson & Johnson) is the latest pharmaceutical company to change its wholesaling arrangements in the UK. It will reduce the number of full-line wholesalers that it uses toAAH Pharmaceuticals, Phoenix Healthcare Distribution andUnichem. It will, however, retain the standard wholesaling model for its business. The new arrangements apply to the mainland of Great Britain, and come into effect in January. A number of other UK companies have also limited the number of wholesalers that they deal with over the past few years, and several have altered their business practices so that distributors act as agents rather than as conventional wholesalers.
You may also be interested in...
Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.